| Not Yet Recruiting | Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers NCT07399171 | Halia Therapeutics, Inc. | Phase 2 |
| Not Yet Recruiting | A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutatio NCT06996730 | Banner Health | Phase 2 / Phase 3 |
| Not Yet Recruiting | The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheime NCT07212062 | Neurology Office of South Florida | Phase 2 |
| Not Yet Recruiting | Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD) NCT07073066 | Beijing Tiantan Hospital | N/A |
| Recruiting | A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease NCT07170150 | Hoffmann-La Roche | Phase 3 |
| Recruiting | A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease NCT07169578 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease NCT06489548 | Brigham and Women's Hospital | Phase 2 |
| Recruiting | University of Central Florida Music Study NCT07306065 | University of Central Florida | N/A |
| Not Yet Recruiting | Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry) NCT07058129 | Beijing Tiantan Hospital | — |
| Recruiting | Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease NCT06484244 | Emory University | N/A |
| Recruiting | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies NCT07177352 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease NCT06856681 | C2N Diagnostics | N/A |
| Recruiting | A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD NCT06647498 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Recruiting | A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD NCT05552157 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Enrolling By Invitation | EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES NCT07233512 | Centre Hospitalier Universitaire de Liege | N/A |
| Completed | A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in P NCT05891496 | Novo Nordisk A/S | Phase 3 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Sta NCT05256134 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease NCT05269394 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Terminated | An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US NCT05097131 | Biogen | — |
| Active Not Recruiting | Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, an NCT04639050 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease NCT06424236 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Completed | A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of NCT04023994 | Hoffmann-La Roche | Phase 1 |
| Terminated | A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Dis NCT03131453 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Terminated | A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzh NCT02565511 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care NCT01993836 | Duke University | Phase 4 |
| Completed | Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures NCT02409082 | Sahlgrenska University Hospital | — |
| Unknown | Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia NCT02013518 | Oslo University Hospital | N/A |
| Completed | The Feasibility of Florbetapir Quantitation NCT01946243 | Avid Radiopharmaceuticals | Phase 4 |
| Completed | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease NCT04623242 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Active Not Recruiting | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease NCT01760005 | Washington University School of Medicine | Phase 2 / Phase 3 |
| Terminated | A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 NCT01723488 | Avid Radiopharmaceuticals | EARLY_Phase 1 |
| Terminated | A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807 NCT01733355 | Avid Radiopharmaceuticals | EARLY_Phase 1 |
| Unknown | Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease NCT01642420 | Zealand University Hospital | — |
| Completed | Identifying Potential Effects of Liraglutide on Degenerative Changes NCT01469351 | University of Aarhus | N/A |
| Unknown | Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type NCT01479855 | Oslo University Hospital | — |
| Completed | Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders NCT00911690 | Corewell Health East | — |
| Completed | Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects NCT00456417 | Institute for Neurodegenerative Disorders | Phase 1 |
| Completed | Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls NCT00448799 | Molecular NeuroImaging | Phase 1 |
| Completed | Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Com NCT00439010 | Molecular NeuroImaging | Phase 1 |